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Abstract
Depression is a known risk factor for antiretroviral therapy (ART) non-adherence, but little is known about the mechanisms 
explaining this relationship. Identifying these mechanisms among people living with HIV (PLHIV) after release from prison 
is particularly important, as individuals during this critical period are at high risk for both depression and poor ART adher-
ence. 347 PLHIV recently released from prison in North Carolina and Texas were included in analyses to assess mediation 
of the relationship between depressive symptoms at 2 weeks post-release and ART adherence (assessed by unannounced 
telephone pill counts) at weeks 9–21 post-release by the hypothesized explanatory mechanisms of alcohol use, drug use, 
adherence self-efficacy, and adherence motivation (measured at weeks 6 and 14 post-release). Indirect effects were estimated 
using structural equation models with maximum likelihood estimation and bootstrapped confidence intervals. On average, 
participants achieved 79% ART adherence. The indirect effect of depression on adherence through drug use was statistically 
significant; greater symptoms of depression were associated with greater drug use, which was in turn associated with lower 
adherence. Lower adherence self-efficacy was associated with depressive symptoms, but not with adherence. Depression 
screening and targeted mental health and substance use services for depressed individuals at risk of substance use constitute 
important steps to promote adherence to ART after prison release.
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Introduction
The prevalence of HIV infection among incarcerated persons 
is several times that of the general population [1, 2]. While 
incarcerated people living with HIV (PLHIV) receive and 
largely take treatment successfully during incarceration, many 
have trouble maintaining adherence to antiretroviral therapy 
(ART) after release from prison [3–5], increasing their risk 
of disease progression and transmission to others. Depres-
sion is an important risk factor for medication non-adherence 
[6–8], and is associated with an increased risk of adverse HIV 
health outcomes including mortality [9–15]. The risk posed 
by depression for HIV treatment outcomes is of concern for 
this population, as the prevalence of major depression in U.S. 
state prisoners is estimated to be between 9 and 29% [16], and 
may be as high as 45% among prisoners living with HIV [17]. 
Because of the burden of depression in this population and the 
risk it poses for ART non-adherence, there is a need to under-
stand how depressive symptoms negatively affect adherence to 
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ART in the critical period after release from prison to inform 
targeted interventions.
At present, there is limited understanding of the mecha-
nisms explaining the link between depression and ART non-
adherence [7]. The few existing studies specifically testing 
explanatory mechanisms of the relationship between depres-
sion and adherence suggest four potential mechanisms: (1) 
adherence self-efficacy [18–20]; (2) adherence motivation 
[18]; (3) lifestyle organization and routinization [21], or dif-
ficulty fitting ART regimen into daily lifestyle [22]; and (4) 
substance use [23]. Further studies pertaining to negative 
affect, rather than depression specifically, suggest that con-
cerns about the adverse effects of ART [24], avoidant coping 
[25], and difficulty obtaining medication [22] may also help 
to explain the relationship between negative affect and ART 
non-adherence. Known barriers to ART adherence including 
concentration difficulties, sleep disruption, and poor appetite 
[26]—known symptoms of depression—may also be plausi-
ble explanatory mechanisms linking depression and adherence 
[27]. Importantly, none of these previous mediation studies 
were conducted among incarcerated persons, a key popula-
tion for addressing disparities in HIV clinical outcomes in 
the U.S. Evidence of mechanisms explaining the relationship 
between depression and ART non-adherence in incarcerated 
and recently incarcerated PLHIV is needed to understand how 
to improve treatment outcomes in this important population.
To build this evidence, we aimed to identify explanatory 
mediators of the relationship between depressive symptoms 
and ART adherence in an incarcerated population following 
release from prison using data from a randomized controlled 
trial of an intervention designed to enhance linkage to care 
and ART adherence and for newly released prisoners living 
with HIV [28, 29]. We tested the indirect effect of depressive 
symptoms on adherence to ART through four hypothesized 
mediators, which were selected on the basis of a review of the 
current literature and previous qualitative work with the study 
population [30]: alcohol use, drug use, adherence self-efficacy, 
and adherence motivation. We specifically hypothesized that 
all mediators would independently partially mediate the 
relationship between symptoms of depression 2 weeks after 
release from prison and ART adherence through 24 weeks 
post-release. In testing these mediation hypotheses, our aim 
was to identify cognitive and behavioral targets for future 
interventions aiming to promote ART adherence in the con-




This study was conducted using data from a randomized 
controlled trial of a program designed to promote link-
age to care and ART adherence among PLHIV newly 
released from prison, Project imPACT (Individuals Moti-
vated to Participate in Adherence, Care, and Treatment; 
R01DA030793). The design of the imPACT trial has been 
described previously [28, 29]. Study recruitment took 
place in the North Carolina and Texas criminal justice sys-
tems, which together represent 15% of all persons in U.S. 
state prisons. Eligible participants were randomized to the 
imPACT intervention arm or standard care. The interven-
tion was designed to promote rapid engagement in HIV 
care after release from prison and consisted of three main 
components: motivational interviewing before and after 
release, pre-release needs assessment and medical care 
link coordination, and text message reminders for each 
antiretroviral medication dose. The data presented in the 
current study are taken from questionnaires and pill-count 
measures of ART adherence collected longitudinally after 
release from prison for the evaluation of this trial.
Study Participants and Procedures
PLHIV incarcerated within the Texas Department of 
Criminal Justice or North Carolina Department of Pub-
lic Safety were recruited to participate. To be eligible for 
enrollment in the imPACT trial, participants had to be 
English-speaking, at least 18 years of age, treated with 
ART, virally suppressed (plasma HIV RNA level < 400 
copies/mL) within 90 days prior to release, and willing and 
able to provide written consent. Participants also needed to 
have an expected prison release date within approximately 
12 weeks after enrollment and to not have been convicted 
of violent offenses in order to minimize risk to study staff. 
Enrollment began in March 2012 and all study procedures 
were completed by February 2015. A total of 405 partici-
pants were enrolled in Texas (n = 242) and North Carolina 
(n = 163), and 381 total participants were randomized to 
the study arms. There were 24 withdrawals from the study 
following randomization due to ineligibility (primarily due 
to sentence extensions or threats to the safety of study 
staff). Forty-one participants (11%) were reincarcerated 
by week 9 post-release and 63 (17%) were reincarcerated 
by 21 weeks post-release. Participants completed a base-
line study visit in prison and an additional pre-release 
visit approximately 2–4 weeks before anticipated release. 
Post-release study visits were scheduled at weeks 2, 6, 
14, and 24 after release, at which time participants com-
pleted behavioral questionnaires and other study proce-
dures. Unannounced pill counts were conducted by phone 
at weeks 1, 5, 9, 13, 17, and 21 after release.
Ethical Review
All study procedures were approved by the institutional 
review boards of Texas Christian University (TCU) and the 
University of North Carolina at Chapel Hill (UNC), as well 
as by human subjects committees at each prison system and 
authorized by the US Office of Human Research Programs 




The primary outcome of the present analysis was adherence 
to ART measured by pill counts. Study staff conducted 
monthly unannounced phone-based pill counts, which have 
been shown to be a valid, objective measure of ART adher-
ence [31–33]. A baseline pill count was conducted shortly 
after release to account for all medications. During each 
monthly pill count, participants were asked to count and 
report how many pills they had remaining in their monthly 
pill bottle. The expected number of pills a participant should 
have had remaining that month was determined using pre-
scription label data and the number of pills dispensed, as 
reported over the phone by the participant. The observed 
number of pills taken since the previous count was calcu-
lated as the number of counted pills subtracted from the 
number of pills at the previous count, adjusting for pills 
dispensed and any other gains and losses. Similarly, the 
expected number of pills taken since the prior count was 
calculated based on the number of intervening days and 
the prescribed number of pills to be taken per day. Adher-
ence was calculated as a ratio of the observed pills taken to 
expected pills taken, resulting in a continuous proportion 
ranging from 0 to 1. A mean proportion of adherence was 
calculated across pill counts taken at weeks 9, 13, 17, and 
21 for analysis.
Depressive symptoms were measured at 2 weeks after 
release using the modified Texas Christian University 
Psychological Functioning (TCU PSY) Form, which has 
demonstrated high reliability and validity in this popula-
tion [34, 35]. Participants were asked to rate the extent to 
which 6 depressive symptoms applied to them on a five-
point Likert-type scale ranging from 1 “disagree strongly” 
to 5 “agree strongly.” Participants were asked if in general 
they would say that they: (1) feel interested in life; (2) feel 
sad or depressed; (3) feel extra tired or run down; (4) worry 
or brood a lot; (5) feel hopeless about the future; and (6) feel 
lonely. The depression items showed good internal consist-
ency in the study sample at 2 weeks post-release (Cronbach’s 
Alpha = 0.83). A depressive symptom score for each par-
ticipant was calculated as the mean of their responses to the 
6 items (range 1–5, with a higher score indicating a higher 
level of depressive symptoms).
Hypothesized Mediators
Substance Use Alcohol use was measured using the Alco-
hol Use Disorders Identification Test (AUDIT) [36] at weeks 
6 and 14 post-release. Participants were asked a series of 10 
questions about the frequency of alcohol use and alcohol-
related events over the past 30 days rated on a scale from 0 
to 4. A sum score was calculated ranging from 0 to 40 with 
greater scores indicating more severe alcohol use [36]. A 
score of 8 or more is associated with harmful or hazardous 
drinking, and a score of 13 or more in women or 15 or more 
in men indicates likely alcohol dependence [36]. Drug use 
over the past 30 days was measured using the TCU Drug 
Screen [34, 37] at weeks 6 and 14 post-release. Participants 
were asked a set of 9 yes/no questions about their use of ille-
gal drugs or prescription medications for non-medical rea-
sons over the past 30 days. A sum score of “yes” responses 
was calculated for each participant ranging from 0 to 9 with 
a score of 3 or greater indicating likely drug dependence 
[38]. Mean values of alcohol use and drug use scores for 
weeks 6 and 14 were calculated for analysis.
Cognitive Mediators Adherence self-efficacy and motiva-
tion were each measured at weeks 6 and 14 post-release. 
Adherence self-efficacy was measured using the HIV Treat-
ment Adherence Self-Efficacy Scale (HIV-ASES) [39]. 
Participants were asked to rate 12 items projecting their 
perceived self-efficacy to adhere to their ART regimen over 
the next 30 days (e.g. “In the next 30 days, how confident 
are you that you can: Fit taking your HIV medicines into 
your daily routine?”) on a 10-point scale (range: 0 “cannot 
do at all” to 10 “completely certain can do”), and a mean 
of the items was taken to create a total score. The adher-
ence self-efficacy items showed good internal consistency 
in the study sample at baseline (Cronbach’s Alpha = 0.93). 
The adherence motivation measure used was adapted from 
a measure of motivation to practice safer sex used in the 
Safe Talk study, with items modified to reflect ART adher-
ence rather than safe-sex practices [40]. Participants were 
asked to rate 7 items projecting their motivation to adhere 
to their ART regimen over the next 30  days (e.g. “In the 
next 30 days, how important or unimportant will it be to you 
to stop whatever you are doing to take your HIV medicine 
on time?”) on either a three-point or four-point scale, and a 
sum of the items was taken to create a total score (range 0 
to 24). The adherence motivation items showed good inter-
nal consistency in the study sample at baseline (Cronbach’s 
Alpha = 0.75). Mean values of adherence motivation and 
self-efficacy scores for weeks 6 and 14 were calculated for 
analysis.
Analysis
Participants who were not reincarcerated within 9 weeks of 
release from prison are included in the analyses presented. 
Descriptive statistics of participant demographic character-
istics and key analytic variables were generated in SAS ver-
sion 9.4. The total effect of depression on ART adherence (c 
path; see path diagram Fig. 1), the direct effect of depression 
on adherence controlling for all mediators and covariates (c′ 
path), path effects of depression on each mediator (a paths), 
path effects of each mediator on ART adherence (b paths), 
and indirect effects of depression on adherence through each 
mediator were estimated using structural equation models 
with maximum likelihood estimation and bootstrapped con-
fidence intervals in Mplus version 8. All models controlled 
for age, sex, treatment arm, and state of incarceration. The 
presence of statistical mediation was determined by boot-
strapped confidence intervals based on 10,000 bootstrap 
resamples of each estimated indirect effect.
We assessed two assumptions necessary for the causal 
interpretation of observed indirect effects [41]: (1) additiv-
ity of mediated effects; and (2) sequential ignorability (no 
unmeasured pre-exposure confounders). We first assessed 
the assumption of additivity of indirect effects, or the 
assumption that there are no interactions or mutual cau-
sation between the mediators, and no exposure–mediator 
interactions [42]. To do this, we tested interaction terms for 
all combinations of the four hypothesized mediators, and 
theoretically and quantitatively assessed potential causal 
relationships between the mediators. No significant interac-
tions between the mediators were found, and while there 
were significant correlations between some of the mediators 
(ranging in absolute value from 0.12 to 0.42), based on our 
review of these potential relationships in the literature, we 
found that the larger correlations were likely attributable 
to a common cause, such as depressive symptoms, rather 
than to mutual causality. There was no significant interac-
tion between the exposure (depressive symptoms) and any 
mediator. Finally, to assess the robustness of our results to 
potential unmeasured pre-exposure confounding (sequential 
ignorability assumption, i.e., no unmeasured confounding 
variables of the effect of X on M assessed prior to X, and 
no unmeasured confounding variables of the effect of M on 
Y assessed prior to X), we conducted sensitivity analyses 
to estimate the predicted indirect effect for each mediator 
for which the observed effect was statistically significant 




347 participants who were not reincarcerated within 9 weeks 
of prison release were included in the analyses. The majority 
were male (78%), and on average 43 years of age. Two-thirds 
of participants were black (68%) and a quarter were white 
(24%). Participants had been incarcerated for an average of 
2 years. Most participants had a high school education or 
less (74%) and had never been married (63%).
On average, participants achieved 79% ART adherence 
over weeks 9–21 post-release. The average depressive 
symptom score at 2 weeks post-release was 2 (range 1–5, 
with higher scores indicating greater symptom severity). At 
weeks 6 and 14 post-release, 57% of participants reported 
any alcohol use and 24% reported any drug use. Thirteen 
percent of participants had an AUDIT score at either week 
6 or 14 indicating hazardous alcohol use (score ≥ 8). Partici-
pants’ reported adherence self-efficacy was high at weeks 
Fig. 1  Path diagram of mediation hypotheses
6 and 14, with a mean score of 9.6 out of a total possible 
score of 10. Reported adherence motivation was also high, 
with a mean score of 22 out of a total possible score of 24 
(Table 1).
Path Effects
Effects corresponding to the “a” (depression to media-
tor), “b” (mediator to adherence), and total effect “c” 
paths are reported in Table 2 (see Fig. 2 for path depic-
tion of estimates). The total effect of depressive symp-
toms on adherence was non-significant (c path: β = 0.009; 
95% CI − 0.016, 0.035). In the case of a non-significant 
total effect, mediation is still possible if the direction of 
the indirect effect is the opposite of the total effect [45]. 
Alcohol use was not associated with depressive symptoms 
 (a1 path: β = 0.195; 95% CI − 0.231, 0.676), or adher-
ence  (b1 path: β = 0.001; 95% CI − 0.005, 0.006). How-
ever, greater depressive symptoms were associated with 
greater drug use  (a2 path: β = 0.161; 95% CI 0.069, 0.280), 
which was in turn associated with lower adherence  (b2 
path: β = − 0.047; 95% CI − 0.090, − 0.005). Adherence 
self-efficacy was associated with depressive symptoms  (a3 
path: β = − 0.127; 95% CI − 0.230, − 0.031), but not with 
adherence  (b3 path: β = − 0.004; 95% CI − 0.034, 0.035). 
Adherence motivation was not associated with depressive 
symptoms  (a4 path: β = − 0.196; 95% CI − 0.535, 0.079), 
or adherence  (b4 path: β = 0.007; 95% CI − 0.004, 0.021). 
Table 1  Participant 
characteristics (n = 347)*
*Reported at baseline unless otherwise noted
No.(%) or mean ± SD
Age (years) 42.5 ± 9.6





Hispanic ethnicity 27 (1.8%)
Incarceration length (y) 2.0 ± 3.2
Education level
 Some high school 135 (38.9%)
 High school/GED 123 (35.5%)
 Some college/trade school 89 (25.7%)
Marital status
 Married 55 (15.9%)
 Formerly married 74 (21.3%)
 Never married 218 (62.8%)
Mean adherence (weeks 9–21) 79.3% ± 18.1%
Depressive symptoms (week 2) 2.1 ± 0.9
Alcohol use (AUDIT)
 Mean score weeks 6 & 14 2.3 ± 4.1
 Any alcohol use weeks 6 & 14 169 (57.1%)
 Hazardous alcohol use week 6 or 14 (score ≥ 8) 39 (13.4%)
 Likely alcohol dependence week 6 or 14 (women ≥ 13; men ≥ 15) 13 (4.5%)
Drug use
 Mean score weeks 6 & 14 0.2 ± 0.8
 Any drug use weeks 6 & 14 71 (24.3%)
 Likely drug dependence (score ≥ 3) 4 (1.4%)
 Drug use type (any use in past 30 days at week 6 or 14)
  Cannabis 50 (17.2%)
  Cocaine (any form) 43 (14.8%)
  Other 23 (7.9%)
Adherence self-efficacy (mean weeks 6 & 14) 9.6 ± 0.8
Adherence motivation (mean weeks 6 & 14) 21.9 ± 2.1
Mediation: Indirect and Direct Effects
Despite a non-statistically significant total effect, the 
total indirect effect for all four mediators was significant 
(Table 2; β = − 0.008; 95% CI − 0.021, − 0.001). Most 
of the total indirect effect was attributable to the signifi-
cant indirect effect of depression on adherence through 
drug use (β = − 0.007; 95% CI − 0.019, − 0.001). No other 
individual indirect effects were statistically significant. 
For the total mediated model, the direct effect (effect of 
depressive symptoms on adherence controlling for all 
mediators and covariates) was non-statistically significant 
(c′ path: β = 0.010; 95% CI − 0.005, 0.006), slightly larger 
than the total effect (c path: β = 0.009; 95% CI − 0.016, 
0.035), and in the opposite direction of the indirect effect, 
indicating inconsistent mediation or suppression of the 
relationship between depressive symptoms and ART 
adherence by drug use [45].
Sensitivity Analysis
To assess the extent to which the observed indirect effect 
through drug use was robust to unmeasured pre-exposure 
confounders, we estimated the predicted indirect effect at 
various values of ρ, or the correlation of the model resid-
ual for adherence and the model residual for drug use. We 
found that the significance of the observed indirect effect 
was robust for all positive values of ρ, but that the effect 
was predicted to be non-significant for negative values of ρ 
exceeding approximately − 0.05 (Fig. 3). A negative value of 
ρ might be expected if individuals had lower drug use than 
expected given depressive symptoms, and also had higher 
levels of adherence than would be expected given their levels 
of drug use and depressive symptoms. This issue could also 
arise if individuals had higher drug use than expected given 
depressive symptoms, and also had lower levels of adher-
ence than would be expected given their levels of drug use 
Table 2  Adjusted coefficient estimates for path, indirect, direct, and total effects
All models include age, sex, treatment arm, and state of incarceration as covariates
Bolded estimates are statistically significant (non-zero 95% confidence interval)
Mediator (M) Effect of depression 
on M (a)
Effect of M on 
adherence (b)
Indirect effect Total indirect effect Direct effect (c′) Total effect (c)
Alcohol use 0.195 (− 0.231, 
0.676)
0.001 (− 0.005, 
0.006)
0.000 (− 0.001, 
0.003)
− 0.008 (− 0.021,
− 0.001)
0.010 (− 0.005, 
0.006)
0.009 (− 0.016, 
0.035)
Drug use 0.161 (0.069, 
0.280)
− 0.047 (− 0.090,
− 0.005)




− 0.127 (− 0.230,
− 0.031)
− 0.004 (− 0.034, 
0.035)




− 0.196 (− 0.535, 
0.079)
0.007 (− 0.004, 
0.021)
− 0.001 (− 0.006, 
0.001)
Fig. 2  Adjusted coefficient estimates for path, direct, and total effects
and depressive symptoms. We have no reason to expect that 
either of these scenarios would be likely to occur.
Discussion
PLHIV recently released from prison with more severe 
depressive symptoms reported higher levels of drug use, 
and those reporting greater drug use in turn had lower lev-
els of adherence to ART. The indirect (mediated) effect of 
depression on adherence through drug use was statistically 
significant, while the total effect of depression on ART 
adherence was not significant in this population. This pattern 
of mediation, known as suppression [43], indicates the exist-
ence of an unobserved alternative pathway by which greater 
depressive symptoms are associated with higher adherence. 
We found no evidence to support alcohol use, adherence 
self-efficacy, or adherence motivation as mediators of the 
relationship between depression and adherence. We discuss 
these findings and implications for research and practice in 
detail below.
Drug Use Links Depression to Lower ART Adherence
The primary hypothesis supported by the results was that of 
the mediating role of drug use in the relationship between 
depressive symptoms and adherence to ART. Participants 
with greater depressive symptoms reported higher levels of 
drug use, and those reporting greater drug use in turn had 
lower levels of adherence to ART. Our results suggest that 
PLHIV recently release from prison with elevated depres-
sive symptoms may be at risk of greater substance use, and 
therefore lower ART adherence.
We are aware of only one previous study evaluating drug 
use as a mediator of the relationship between depression 
and adherence [23], the results of which did not support 
drug use as a mechanism explaining this relationship in a 
population of non-incarcerated men who have sex with men 
(MSM) in the U.S. Given the preponderance of evidence 
linking depression and drug use [46], and drug use and 
adherence [47, 48], it would follow that drug use should, 
at least partially, explain the relationship between depres-
sion and adherence. Models of cognitive escape suggest 
that negative or depressed affect can lead to avoidant cop-
ing behaviors [49], such as substance use, which lead to 
cognitive disengagement that decreases the likelihood of 
maintaining healthy behaviors, such as medication adher-
ence [50]. In previous qualitative work with the study popu-
lation, we found that many PLHIV struggle to maintain ART 
adherence after release from prison, and often link these 
lapses in adherence to substance use [30]. Participants in the 
qualitative study described the high availability of drugs and 
relationships with drug using social networks in their home 
communities as factors precipitating their drug use [30]. 
Understanding this context may help to understand why drug 
use is an important mechanism in the depression–adherence 
relationship in this population while it may not be in others.
The pattern of mediation by drug use of the relationship 
between depressive symptoms and ART adherence indicated 
suppression, or inconsistent mediation, of the relationship by 
drug use [45], with the indirect effect through drug use being 
negative, and the direct effect being positive and slightly 
larger than the total effect (which was non-significant). This 
pattern of mediation suggests that there are one or more 
unobserved mechanisms through which greater depressive 
symptoms may actually be associated with higher ART 
adherence, explaining the non-significant total relationship 
observed between depressive symptoms and adherence 
in this population [45]. While in the present study we are 
unable to elucidate reasons for which greater symptoms 
of depression may be associated with higher adherence in 
some cases, one potential scenario may be that some patients 
with high levels of depressive symptoms may be likely to be 
referred to mental health treatment services. Receipt of these 
services may lead to higher levels of adherence for these 
individuals as compared to their peers not receiving these 
services. Few studies have found such a positive association 
between depression and ART adherence. In one case, ART 
adherence was higher in PLHIV diagnosed with depres-
sion (HIV-infected drug users enrolled in New York State 
Medicaid) [51]. The authors of this study further found that 
over 80% of individuals diagnosed with depression received 
either psychiatric care or antidepressant therapy, and only 
one-third with no such diagnosis received mental health ser-
vices. Together, these results suggest that mental health care 
utilization may help to explain the potential for higher adher-
ence among certain depressed individuals. Intervention stud-
ies delivering mental health and substance use services to 
PLHIV indicate that these strategies can effectively promote 
adherence among individuals diagnosed with depression [8, 
Fig. 3  Sensitivity analysis: estimated indirect effect and confidence 
interval by values of ρ
52], suggesting that utilization of these services may serve 
to mitigate (modify) the relationship between depression 
and ART non-adherence. To formally assess this hypoth-
esis, future studies should test the extent to which receipt of 
mental health and substance use services modifies the rela-
tionship between depression, drug use, and ART adherence.
While this alternative mechanism remains to be under-
stood, our results do indicate that symptoms of depression 
may be an important risk-factor for drug use following 
release from prison, and therefore for lower adherence to 
ART. This mechanism may be salient for other populations, 
as an estimated one-third of PLHIV suffer from depression 
[53], and up to 60% of PLHIV will experience a substance 
use disorder in their lifetime [54–56]. Our results emphasize 
the importance of considering both depression and substance 
use history in identifying individuals for targeted adherence 
interventions during the critical period after release from 
prison. A number of strategies exist for the treatment of co-
occurring mood and substance use disorders, including indi-
vidual and group counseling [57], contingency management 
approaches [58], and pharmacotherapies [46]. Successful 
treatment may allow PLHIV with substance use disorders to 
achieve similar HIV treatment outcomes to their peers who 
do not use drugs [59]. While many evidence-based treat-
ments for co-occurring depression and substance use disor-
ders exist, effective strategies to facilitate linkage to these 
services during community re-entry are needed. One such 
program for linkage to care is the Assess, Plan, Identify, and 
Coordinate (APIC) model [60]. In this system-level model, a 
coordinating committee of prison representatives and com-
munity providers coordinate to facilitate access to men-
tal health and substance use treatment during community 
reentry [60]. The primary elements of this model include a 
comprehensive needs assessment for each individual prior to 
reentry, system- and individual-level planning for treatment 
and service provision, identification of programs responsi-
ble for post-release services, and coordination of care as 
individuals transition from prison to the community [60]. 
The potential for this and other system-level models to not 
only increase access to behavioral health services but also to 
promote retention in and adherence to HIV treatment should 
be evaluated.
Unsupported Mediation Hypotheses
We did not find support for the cognitive attributes of adher-
ence self-efficacy and adherence motivation as explanatory 
mediators in the relationship between depressive symptoms 
and ART adherence in this population of recently incar-
cerated PLHIV. Previous studies have found support for 
adherence self-efficacy as a mediator of this relationship in 
clinical populations in the U.S. [19, 61], and Uganda [18]. 
While we did find that greater depressive symptoms were 
associated with lower adherence self-efficacy in this popu-
lation, greater adherence self-efficacy was not associated 
with higher ART adherence. We also did not find adherence 
motivation to be associated with either depressive symptoms 
or adherence. One previous study found some support for 
adherence motivation as a mediator of the depression–adher-
ence relationship, but further found that when adherence 
self-efficacy was introduced as a competing mediator, the 
indirect effect through adherence motivation was no longer 
statistically significant [18]. In addition, empirical [19] and 
theoretical [62] models suggest that adherence motivation 
may be an important precursor to adherence self-efficacy. 
Taken together, this suggests that adherence self-efficacy 
may be a more proximate determinant of adherence behavior 
than adherence motivation, though we found no support for 
either mechanism. One reason for this null finding could be 
the very high self-reported levels of adherence self-efficacy 
and motivation in this population, creating potential ceiling 
effects in the ability to observe significant associations with 
these variables. Alternatively, these cognitive constructs 
may be less relevant explanatory mechanisms in the link 
between depressive symptoms and ART adherence in this 
population than in others. While our results support the rela-
tionship between depressive symptoms and lower adherence 
self-efficacy, it may simply be the case that self-efficacy is 
not the most important limiting factor in ART adherence in 
this population.
Our results also did not support alcohol use as a mecha-
nism explaining the depression–adherence relationship. One 
previous study did find that alcohol use partially explained 
the relationship between depression and appointment adher-
ence, but not medication adherence, among men living with 
HIV in Chicago [23]. Other studies support the link between 
depression and alcohol use [63–65], and between alcohol 
use and ART non-adherence [66] separately. Given this 
evidence, it would seem likely that alcohol use would be 
an important mechanism linking depressive symptoms and 
ART non-adherence. Though this hypothesis was not sup-
ported in this population, it should be noted that the level of 
reported alcohol use in this population was relatively low. 
Given the paucity of studies evaluating alcohol use as a 
mediator of the relationship between depression and adher-
ence, more research is needed to understand the explanatory 
power of the use of alcohol and other substances in this 
relationship.
Limitations
The results of this study should be interpreted with key 
limitations in mind. Depressive symptoms were measured 
through self-report, thus we cannot assume a clear relation-
ship between the magnitude of these reported symptoms and 
a clinical diagnosis. About two-fifths of pill counts were 
missed due to missed contacts, re-incarceration, and loss to 
follow-up. Potential bias in estimates associated with adher-
ence based on missing pill counts was mitigated through 
the use of maximum likelihood estimation. Measurement 
of ART adherence through unannounced telephone pill 
counts may be imperfect because counts cannot be visu-
ally confirmed, but the evidence supports these counts as a 
valid and reliable measure of adherence [31–33]. In testing 
hypotheses related to adherence self-efficacy and motiva-
tion, there may have been ceiling effects in the ability to 
detect significant associations given that reported scores on 
both measures were high. Given that the intervention being 
evaluated in the parent trial aimed to increase adherence 
motivation and self-efficacy, treatment group participants 
may have been particularly susceptible to social desirabil-
ity bias in reporting these measures. Recently incarcerated 
persons may also be wary of reporting substance use, but 
participants were ensured of the confidentiality of their dis-
closures in response to study questionnaires to encourage 
candor. The observed associations cannot necessarily be 
assumed to be causal, but given the temporality of observa-
tions and apparent robustness of the observed relationships 
to unmeasured confounders, there is some ground to infer 
causal relationships where significant associations were 
found. The results of this study may not be generalizable to 
individuals who have not achieved viral suppression while 
incarcerated, or to individuals convicted of violent crimes. 
Of the 1802 individuals assessed for eligibility, 307 (17%) 
were ineligible because they were not virally suppressed 
(plasma HIV RNA < 400 copies/mL) within 90 days prior 
to release from prison. Despite this restriction of eligibility, 
participants in this study did display a wide range of adher-
ence levels during the observation period after release from 
prison (mean = 79.3%, SD = 18.1%). Fourteen percent (247) 
of individuals approached were ineligible because they had 
been convicted of violent offenses such as those related to 
sexual assault, serious injury, or death (to minimize risk to 
study staff). Finally, the context of incarceration and home 
communities of recently incarcerated persons in Texas and 
North Carolina may be qualitatively different than those in 
other states and regions of the U.S. While we cannot say 
that the study population is representative of all incarcerated 
populations in the U.S., it does represent an important incar-
cerated population as prisoners in these two states represent 
one-seventh of all prisoners in the country.
Conclusion
Our results indicate that PLHIV recently released from 
prison who suffer f rom depression are a t increased r isk 
of drug use, and therefore may have lower levels of ART 
adherence. Given the burden of depression in incarcerated 
populations, and overwhelming evidence linking depression 
and ART non-adherence, approaches to mitigate this rela-
tionship are needed. Our findings suggest that screening for 
depression and targeting mental health services to depressed 
individuals at risk of substance use constitute important 
steps to promote adherence to ART after prison release.
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